A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

被引：379

作者：

Cobleigh, MA

Langmuir, VK

Sledge, GW

Miller, KD

Haney, L

Novotny, WF

Reimann, JD

Vassel, A

机构：

[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA

[2] Genentech Inc, San Francisco, CA USA

[3] Indiana Univ, Indianapolis, IN 46204 USA

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 05期

关键词：

D O I：

10.1053/j.seminoncol.2003.08.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：117 / 124

页数：8

共 20 条

[1]

Borgström P, 1999, ANTICANCER RES, V19, P4203

[2] EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) AND ITS RECEPTORS IN BREAST-CANCER [J].

BROWN, LF ;

BERSE, B ;

JACKMAN, RW ;

TOGNAZZI, K ;

GUIDI, AJ ;

DVORAK, HF ;

SENGER, DR ;

CONNOLLY, JL ;

SCHNITT, SJ .

HUMAN PATHOLOGY, 1995, 26 (01) :86-91

[3]

BROWN LF, 1997, EXS, V79, P233, DOI DOI 10.1007/978-3-0348-9006-9_10

[4]

DEVORE RF, 2000, P AN M AM SOC CLIN, V19, P485

[5] Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].

Ferrara, N ;

CarverMoore, K ;

Chen, H ;

Dowd, M ;

Lu, L ;

OShea, KS ;

PowellBraxton, L ;

Hillan, KJ ;

Moore, MW .

NATURE, 1996, 380 (6573) :439-442

[6]

Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1

[7]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

[8] CLINICAL IMPORTANCE OF THE DETERMINATION OF TUMOR ANGIOGENESIS IN BREAST-CARCINOMA - MUCH MORE THAN A NEW PROGNOSTIC TOOL [J].

GASPARINI, G ;

HARRIS, AL .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :765-782

[9] Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer [J].

Gordon, MS ;

Margolin, K ;

Talpaz, M ;

Sledge, GW ;

Holmgren, E ;

Benjamin, R ;

Stalter, S ;

Shak, S ;

Adelman, DC .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :843-850

[10]

Granger JP, 2000, ACTA PHYSIOL SCAND, V168, P161

← 1 2 →